Immuneering to Participate in Jefferies 2021 London Healthcare Conference
November 10 2021 - 6:50AM
Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
advancing a robust pipeline of oncology and neuroscience product
candidates that are designed to uniquely disrupt cellular signaling
dynamics, today announced that Company management will participate
in the upcoming Jefferies 2021 London Healthcare Conference, taking
place virtually and in-person from November 16-19, 2021 in London,
England. At the conference, Ben Zeskind, Ph.D., Co-Founder,
President and Chief Executive Officer of Immuneering, Biren Amin,
MBA, Chief Financial Officer and Brett Hall, Ph.D., Chief
Scientific Officer, will participate virtually to share commentary
with investors around the Company’s pipeline, platform and business
strategy.
Immuneering will present virtually at the Jefferies London
Healthcare Conference as follows:
Date: |
|
|
Thursday, November 18, 2021 |
|
|
|
|
Time: |
|
|
08:00 Greenwich Mean Time / 03:00 AM Eastern time |
|
|
|
|
Webcast: |
|
|
https://wsw.com/webcast/jeff201/register.aspx?conf=jeff201&page=imrx&url=https://wsw.com/webcast/jeff201/imrx/1865664 |
The presentation will be webcast live and available on
demand from November 18, 2021 at 3:00 am ET to
November 19, 2021 at 12:00 pm ET at the above
link.
About Immuneering
Corporation Immuneering
is a biopharmaceutical company with an emerging pipeline focused on
improving patient outcomes across a spectrum of debilitating
oncologic and neurologic diseases by applying its deep knowledge of
translational bioinformatics to every stage of the drug development
process. Immuneering has more than a decade of experience in
translational bioinformatics and generating insights into drug
mechanisms of action and patient treatment responses. Building on
this experience, Immuneering has developed a disease-agnostic
platform that enables the company to utilize human data, novel
biology and chemistry, and translational planning to create and
advance its wholly owned pipeline. Immuneering’s current
development programs in oncology are focused on providing potential
treatments for patients with solid tumors caused by mutations of
oncologic signaling pathways, including the MAPK pathway.
Immuneering’s lead product candidate, IMM-1-104, is designed to be
a highly selective dual-MEK inhibitor that further disrupts KSR for
the treatment of advanced solid tumors in patients harboring RAS
mutant tumors. Additionally, Immuneering has six other oncology
programs in the discovery stage that are designed to target either
the MAPK or mTOR pathway, and two neuroscience programs in the
discovery
stage.
Forward-Looking Statements
This press release includes certain disclosures
that contain "forward-looking statements." Forward-looking
statements are based on Immuneering’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Factors that could cause actual results to
differ include, but are not limited to, the risks inherent in
oncology and neuroscience drug development, including target
discovery, target validation, lead compound identification, lead
compound optimization, preclinical studies and clinical trials.
These and other risks and uncertainties are described more fully in
the section titled "Risk Factors" in the final prospectus related
to the offering filed with the U.S. Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Immuneering undertakes
no duty to update such information except as required under
applicable law.
Corporate Contact:Rebecca Kusko,
Ph.D.Immuneering Corporation617-500-8080rkusko@immuneering.com
Investor Contact:Anne Marie FieldsManaging
DirectorRx Communications afields@rxir.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024